Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124057 | 0.71 | NTRK1 (0.31) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL422300 | 0.71 | CCR1 (0.44) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL26481149 | 0.67 | NCF1 (0.44) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL21388633 | 0.67 | LMNA (0.37) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL843037 | 0.67 | SOS2 (0.39) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL26977519 | 0.67 | CCR1 (0.50) | NTRK1NTRK2CLK4 | |
| SCHEMBL12940677 | 0.67 | ELANE (0.33) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL9934727 | 0.67 | ELANE (0.33) | NTRK1NTRK2CLK4 | |
| SCHEMBL10299 | 0.63 | — | — | |
| SCHEMBL3604842 | 0.62 | LMNA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | NTRK1 627/4885LTK 780/4885TYRO3 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.